These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 26305408)
1. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Roth M; Barris DM; Piperdi S; Kuo V; Everts S; Geller D; Houghton P; Kolb EA; Hawthorne T; Gill J; Gorlick R Pediatr Blood Cancer; 2016 Jan; 63(1):32-8. PubMed ID: 26305408 [TBL] [Abstract][Full Text] [Related]
2. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer. Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941 [TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761 [TBL] [Abstract][Full Text] [Related]
4. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Kolb EA; Gorlick R; Billups CA; Hawthorne T; Kurmasheva RT; Houghton PJ; Smith MA Pediatr Blood Cancer; 2014 Oct; 61(10):1816-21. PubMed ID: 24912408 [TBL] [Abstract][Full Text] [Related]
5. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Ott PA; Pavlick AC; Johnson DB; Hart LL; Infante JR; Luke JJ; Lutzky J; Rothschild NE; Spitler LE; Cowey CL; Alizadeh AR; Salama AK; He Y; Hawthorne TR; Bagley RG; Zhang J; Turner CD; Hamid O Cancer; 2019 Apr; 125(7):1113-1123. PubMed ID: 30690710 [TBL] [Abstract][Full Text] [Related]
6. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Naumovski L; Junutula JR Curr Opin Mol Ther; 2010 Apr; 12(2):248-57. PubMed ID: 20373269 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group. Kopp LM; Malempati S; Krailo M; Gao Y; Buxton A; Weigel BJ; Hawthorne T; Crowley E; Moscow JA; Reid JM; Villalobos V; Randall RL; Gorlick R; Janeway KA Eur J Cancer; 2019 Nov; 121():177-183. PubMed ID: 31586757 [TBL] [Abstract][Full Text] [Related]
8. Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer. Rose AAN; Biondini M; Curiel R; Siegel PM Pharmacol Ther; 2017 Nov; 179():127-141. PubMed ID: 28546082 [TBL] [Abstract][Full Text] [Related]
9. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin. Biondini M; Kiepas A; El-Houjeiri L; Annis MG; Hsu BE; Fortier AM; Morin G; Martina JA; Sirois I; Aguilar-Mahecha A; Gruosso T; McGuirk S; Rose AAN; Tokat UM; Johnson RM; Sahin O; Bareke E; St-Pierre J; Park M; Basik M; Majewski J; Puertollano R; Pause A; Huang S; Keler T; Siegel PM Oncogene; 2022 Mar; 41(12):1701-1717. PubMed ID: 35110681 [TBL] [Abstract][Full Text] [Related]
10. Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE). Vaklavas C; Forero A BioDrugs; 2014 Jun; 28(3):253-63. PubMed ID: 24496926 [TBL] [Abstract][Full Text] [Related]
11. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530 [TBL] [Abstract][Full Text] [Related]
12. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096 [TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. Ott PA; Hamid O; Pavlick AC; Kluger H; Kim KB; Boasberg PD; Simantov R; Crowley E; Green JA; Hawthorne T; Davis TA; Sznol M; Hwu P J Clin Oncol; 2014 Nov; 32(32):3659-66. PubMed ID: 25267741 [TBL] [Abstract][Full Text] [Related]
14. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Kuan CT; Wakiya K; Dowell JM; Herndon JE; Reardon DA; Graner MW; Riggins GJ; Wikstrand CJ; Bigner DD Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1970-82. PubMed ID: 16609006 [TBL] [Abstract][Full Text] [Related]
15. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Keir CH; Vahdat LT Expert Opin Biol Ther; 2012 Feb; 12(2):259-63. PubMed ID: 22229970 [TBL] [Abstract][Full Text] [Related]
16. GPNMB expression in uveal melanoma: a potential for targeted therapy. Williams MD; Esmaeli B; Soheili A; Simantov R; Gombos DS; Bedikian AY; Hwu P Melanoma Res; 2010 Jun; 20(3):184-90. PubMed ID: 20375921 [TBL] [Abstract][Full Text] [Related]
17. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent. Marquez-Nostra BV; Lee S; Laforest R; Vitale L; Nie X; Hyrc K; Keler T; Hawthorne T; Hoog J; Li S; Dehdashti F; Ma CX; Lapi SE Oncotarget; 2017 Nov; 8(61):104303-104314. PubMed ID: 29262642 [TBL] [Abstract][Full Text] [Related]
18. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. Maric G; Rose AA; Annis MG; Siegel PM Onco Targets Ther; 2013; 6():839-52. PubMed ID: 23874106 [TBL] [Abstract][Full Text] [Related]
19. A monoclonal antibody against GPNMB. Zhang P; Li J; Pang X; Yuan X; Li D; Li Y; Guo L; Liu W Monoclon Antib Immunodiagn Immunother; 2013 Aug; 32(4):265-9. PubMed ID: 23909420 [TBL] [Abstract][Full Text] [Related]
20. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Roth M; Linkowski M; Tarim J; Piperdi S; Sowers R; Geller D; Gill J; Gorlick R Cancer; 2014 Feb; 120(4):548-54. PubMed ID: 24166473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]